{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T01:36:30Z","timestamp":1775093790599,"version":"3.50.1"},"reference-count":111,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Cardiac electrophysiology is a constantly evolving speciality that has benefited from technological innovation and refinements over the past several decades. Despite the potential of these technologies to reshape patient care, their upfront costs pose a challenge to health policymakers who are responsible for the assessment of the novel technology in the context of increasingly limited resources. In this context, it is critical for new therapies or technologies to demonstrate that the measured improvement in patients' outcomes for the cost of achieving that improvement is within conventional benchmarks for acceptable health care value. The field of Health Economics, specifically economic evaluation methods, facilitates this assessment of value in health care. In this review, we provide an overview of the basic principles of economic evaluation and provide historical applications within the field of cardiac electrophysiology. Specifically, the cost-effectiveness of catheter ablation for both atrial fibrillation (AF) and ventricular tachycardia, novel oral anticoagulants for stroke prevention in AF, left atrial appendage occlusion devices, implantable cardioverter defibrillators, and cardiac resynchronization therapy will be reviewed.<\/jats:p>","DOI":"10.3389\/fcvm.2023.1142429","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T06:04:26Z","timestamp":1682489066000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Economic evaluation in cardiac electrophysiology: Determining the value of emerging technologies"],"prefix":"10.3389","volume":"10","author":[{"given":"Waseem","family":"Hijazi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bert","family":"Vandenberk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elissa","family":"Rennert-May","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amity","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glen","family":"Sumner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek S.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1161\/CIRCULATIONAHA.116.025037","article-title":"Permanent leadless cardiac pacemaker therapy: a comprehensive review","volume":"135","author":"Tjong","year":"2017","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"835493","DOI":"10.3389\/fcvm.2022.835493","article-title":"The physiologic mechanisms of paced QRS narrowing during left bundle branch pacing in right bundle branch block patients","volume":"9","author":"Zhu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":"Cardiac-resynchronization therapy for the prevention of heart-failure events","volume":"361","author":"Moss","year":"2009","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2029554","article-title":"Cryoballoon ablation as initial therapy for atrial fibrillation","volume":"384","author":"Wazni","year":"2021","journal-title":"N Engl J Med"},{"key":"B5","year":"2021"},{"key":"B6","year":"2022"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1136\/bmj.318.7197.1551","article-title":"Economic notes: opportunity cost","volume":"318","author":"Palmer","year":"1999","journal-title":"Br Med J"},{"key":"B8","volume-title":"The MicraTM transcatheter pacing system, a leadless pacemaker, in patients indi- cated for single-chamber ventricular pacemaker implantation: A single technology assessment","author":"Fagerlund","year":"2018"},{"key":"B9","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3201\/eid0702.010227","article-title":"Applying economic principles to health care","volume":"7","author":"Scott","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/01.CIR.0000021407.93752.7B","article-title":"Medical economics and the assessment of value in cardiovascular medicine: part I","volume":"106","author":"Mark","year":"2002","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/bmb\/ldq033","article-title":"Health outcomes in economic evaluation: the QALY and utilities","volume":"96","author":"Whitehead","year":"2010","journal-title":"Br Med Bull"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1001\/jamacardio.2021.1437","article-title":"Cost-effectiveness of dapagliflozin for treatment of patients with heart failure with reduced ejection fraction","volume":"6","author":"Parizo","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.34172\/ijhpm.2020.244","article-title":"Methods for the economic evaluation of health care interventions for priority setting in the health system: an update from WHO CHOICE","volume":"10","author":"Bertram","year":"2021","journal-title":"Int J Health Policy Manag"},{"key":"B16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the cost-effectiveness of interventions: alternative approaches","volume":"93","author":"Marseille","year":"2015","journal-title":"Bull World Health Organ"},{"key":"B17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2147\/CEOR.S264589","article-title":"Can standard health technology assessment approaches help guide the price of orphan drugs in Canada? A review of submissions to the Canadian agency for drugs and technologies in health common drug review","volume":"12","author":"Balijepalli","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2165\/00019053-200826090-00004","article-title":"The NICE cost-effectiveness threshold: what it is and what that means","volume":"26","author":"McCabe","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/j.jacc.2014.03.016","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American college of cardiology\/American heart association task force on performance measures and task force on practice guidelines","volume":"63","author":"Anderson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/europace\/euaa291","article-title":"Economic evaluation of an absorbable antibiotic envelope for prevention of cardiac implantable electronic device infection","volume":"23","author":"Rennert-May","year":"2021","journal-title":"Europace"},{"key":"B21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13756-018-0327-z","article-title":"Economic evaluations and their use in infection prevention and control: a narrative review","volume":"7","author":"Rennert-May","year":"2018","journal-title":"Antimicrob Resist Infect Control"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/jama.2019.0692","article-title":"Effect of catheter ablation vs. Medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial","volume":"321","author":"Mark","year":"2019","journal-title":"JAMA"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1136\/heartjnl-2021-319496","article-title":"Catheter ablation as first-line treatment for paroxysmal atrial fibrillation: a systematic review and meta-analysis","volume":"107","author":"Imberti","year":"2021","journal-title":"Heart"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1016\/j.jacc.2020.04.065","article-title":"Recurrence of atrial fibrillation after catheter ablation or antiarrhythmic drug therapy in the CABANA trial","volume":"75","author":"Poole","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2212540","article-title":"Progression of atrial fibrillation after cryoablation or drug therapy","volume":"388","author":"Andrade","year":"2022","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure","volume":"379","author":"Marrouche","year":"2018","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/jce.13655","article-title":"Patient and facility variation in costs of catheter ablation for atrial fibrillation","volume":"29","author":"Perino","year":"2018","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1161\/CIRCULATIONAHA.122.058575","article-title":"Cost-effectiveness of catheter ablation versus antiarrhythmic drug therapy in atrial fibrillation: the CABANA randomized clinical trial","volume":"146","author":"Chew","year":"2022","journal-title":"Circulation"},{"key":"B29","first-page":"e2101","article-title":"Ablation procedures for rhythm control in patients with atrial fibrillation: clinical and cost-effectiveness analyses","volume":"2","author":"Assasi","year":"2012","journal-title":"CADTH Technol Overv"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e019599","DOI":"10.1161\/JAHA.120.019599","article-title":"Cost-utility of catheter ablation for atrial fibrillation in patients with heart failure: an economic evaluation","volume":"10","author":"Lau","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"B31","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/j.1540-8167.2007.00902.x","article-title":"Cost comparison of catheter ablation and medical therapy in atrial fibrillation","volume":"18","author":"Khaykin","year":"2007","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/jce.15317","article-title":"Cost-effectiveness of catheter ablation versus medical therapy for the treatment of atrial fibrillation in the United Kingdom","volume":"33","author":"Leung","year":"2022","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.hroo.2020.12.017","article-title":"Catheter ablation and healthcare utilization and cost among patients with paroxysmal versus persistent atrial fibrillation","volume":"2","author":"Friedman","year":"2021","journal-title":"Heart Rhythm O2"},{"key":"B34","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1136\/hrt.2008.147165","article-title":"Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the United Kingdom","volume":"95","author":"McKenna","year":"2009","journal-title":"Heart"},{"key":"B35","doi-asserted-by":"publisher","first-page":"262809","DOI":"10.1155\/2013\/262809","article-title":"Cost-effectiveness of catheter ablation for rhythm control of atrial fibrillation","volume":"2013","author":"Blackhouse","year":"2013","journal-title":"Int J Vasc Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/europace\/euu188","article-title":"The cost-effectiveness of radiofrequency catheter ablation as first-line treatment for paroxysmal atrial fibrillation: results from a MANTRA-PAF substudy","volume":"17","author":"Aronsson","year":"2015","journal-title":"Europace"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e031033","DOI":"10.1136\/bmjopen-2019-031033","article-title":"Modelling the lifetime cost-effectiveness of catheter ablation for atrial fibrillation with heart failure","volume":"9","author":"Gao","year":"2019","journal-title":"BMJ Open"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e007094","DOI":"10.1161\/CIRCOUTCOMES.120.007094","article-title":"Economic evaluation of catheter ablation of atrial fibrillation in patients with heart failure with reduced ejection fraction","volume":"13","author":"Chew","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"B39","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1161\/01.STR.0000254719.26536.a9","article-title":"Stroke prevention in atrial fibrillation: pharmacological rate versus rhythm control","volume":"38","author":"Sherman","year":"2007","journal-title":"Stroke"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.120.050991","article-title":"Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"B41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12872-018-0946-6","article-title":"Resource use and clinical outcomes in patients with atrial fibrillation with ablation versus antiarrhythmic drug treatment","volume":"18","author":"Jarman","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"B42","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.jacep.2020.04.017","article-title":"Quality of life and health care utilization in the CIRCA-DOSE study","volume":"6","author":"Andrade","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41569-020-00451-x","article-title":"Catheter ablation for atrial fibrillation: current indications and evolving technologies","volume":"18","author":"Parameswaran","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2029980","article-title":"Cryoablation or drug therapy for initial treatment of atrial fibrillation","volume":"384","author":"Andrade","year":"2021","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.amjmed.2009.11.025","article-title":"Underuse of oral anticoagulants in atrial fibrillation: a systematic review","volume":"123","author":"Ogilvie","year":"2010","journal-title":"Am J Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"E702","DOI":"10.9778\/cmajo.20210246","article-title":"Geographic and temporal variation in the treatment and outcomes of atrial fibrillation: a population-based analysis of national quality indicators","volume":"10","author":"Chew","year":"2022","journal-title":"CMAJ Open"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1161\/CIRCULATIONAHA.114.010426","article-title":"Cardiology patient page. Warfarin versus novel oral anticoagulants: how to choose?","volume":"130","author":"Wadhera","year":"2014","journal-title":"Circulation"},{"key":"B49","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1161\/STROKEAHA.110.592907","article-title":"Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation","volume":"42","author":"Mercaldi","year":"2011","journal-title":"Stroke"},{"key":"B50","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-154-1-201101040-00289","article-title":"Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation","volume":"154","author":"Freeman","year":"2011","journal-title":"Ann Intern Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"j5058","DOI":"10.1136\/bmj.j5058","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis","volume":"359","author":"Lopez-Lopez","year":"2017","journal-title":"Br Med J"},{"key":"B53","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.repc.2014.08.008","article-title":"Systematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation","volume":"34","author":"Ferreira","year":"2015","journal-title":"Rev Port Cardiol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s40273-013-0087-9","article-title":"Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting","volume":"31","author":"Kleintjens","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"B55","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/CIRCOUTCOMES.113.000661","article-title":"Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation","volume":"6","author":"Canestaro","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"B56","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s11606-013-2639-2","article-title":"Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation\u2013a cost-effectiveness analysis","volume":"29","author":"You","year":"2014","journal-title":"J Gen Intern Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1161\/STROKEAHA.115.012325","article-title":"Cost-effectiveness of oral anticoagulants for ischemic stroke prophylaxis among nonvalvular atrial fibrillation patients","volume":"47","author":"Shah","year":"2016","journal-title":"Stroke"},{"key":"B58","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1001\/jamacardio.2017.0065","article-title":"Economic analysis of apixaban therapy for patients with atrial fibrillation from a US perspective: results from the ARISTOTLE randomized clinical trial","volume":"2","author":"Cowper","year":"2017","journal-title":"JAMA Cardiol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"675200","DOI":"10.3389\/fcvm.2021.675200","article-title":"Cost-effectiveness analysis of direct oral anticoagulants vs. vitamin K antagonists in the elderly with atrial fibrillation: insights from the evidence in a real-world setting","volume":"8","author":"Wu","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/j.cjca.2020.09.001","article-title":"The 2020 Canadian cardiovascular society\/Canadian heart rhythm society comprehensive guidelines for the management of atrial fibrillation","volume":"36","author":"Andrade","year":"2020","journal-title":"Can J Cardiol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1093\/eurheartj\/ehab648","article-title":"Corrigendum to: 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European society of cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"B62","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines and the heart rhythm society","volume":"74","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1001\/jama.2014.15192","article-title":"Percutaneous left atrial appendage closure vs. warfarin for atrial fibrillation: a randomized clinical trial","volume":"312","author":"Reddy","year":"2014","journal-title":"Jama"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes DR","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1016\/j.jacc.2017.10.021","article-title":"5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials","volume":"70","author":"Reddy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e011577","DOI":"10.1161\/JAHA.118.011577","article-title":"Cost-effectiveness of left atrial appendage closure for stroke reduction in atrial fibrillation: analysis of pooled, 5-year, long-term data","volume":"8","author":"Reddy","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.7326\/M21-4653","article-title":"Left atrial appendage occlusion versus oral anticoagulation in atrial fibrillation: a decision analysis","volume":"175","author":"Chew","year":"2022","journal-title":"Ann Intern Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/0272989X15593083","article-title":"A decision analysis of percutaneous left atrial appendage occlusion relative to novel and traditional oral anticoagulation for stroke prevention in patients with new-onset atrial fibrillation","volume":"36","author":"Micieli","year":"2016","journal-title":"Med Decis Making"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1161\/CIRCRESAHA.116.304521","article-title":"The spectrum of epidemiology underlying sudden cardiac death","volume":"116","author":"Hayashi","year":"2015","journal-title":"Circ Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N Engl J Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/eurheartj\/ehl311","article-title":"The high cost of implantable defibrillators","volume":"28","author":"Hlatky","year":"2007","journal-title":"Eur Heart J"},{"key":"B74","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/eurheartj\/ehl166","article-title":"The cost of implantable defibrillators: perceptions and reality","volume":"28","author":"Camm","year":"2007","journal-title":"Eur Heart J"},{"key":"B75","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/clc.22496","article-title":"Gender, racial, and health insurance differences in the trend of implantable cardioverter-defibrillator (ICD) utilization: a United States experience over the last decade","volume":"39","author":"Patel","year":"2016","journal-title":"Clin Cardiol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1161\/CIRCULATIONAHA.113.002539","article-title":"Frequency and determinants of implantable cardioverter defibrillator deployment among primary prevention candidates with subsequent sudden cardiac arrest in the community","volume":"128","author":"Narayanan","year":"2013","journal-title":"Circulation"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1161\/CIRCULATIONAHA.111.066605","article-title":"Trends in use of implantable cardioverter-defibrillator therapy among patients hospitalized for heart failure: have the previously observed sex and racial disparities changed over time?","volume":"125","author":"Al-Khatib","year":"2012","journal-title":"Circulation"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1161\/01.CIR.103.10.1416","article-title":"Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian implantable defibrillator study (CIDS)","volume":"103","author":"O'Brien","year":"2001","journal-title":"Circulation"},{"key":"B79","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1161\/CIRCULATIONAHA.105.581884","article-title":"Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the sudden cardiac death in heart failure trial (SCD-HeFT)","volume":"114","author":"Mark","year":"2006","journal-title":"Circulation"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMsa051989","article-title":"Cost-effectiveness of implantable cardioverter-defibrillators","volume":"353","author":"Sanders","year":"2005","journal-title":"N Engl J Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1016\/j.jacc.2006.03.032","article-title":"The cost effectiveness of implantable cardioverter-defibrillators: results from the multicenter automatic defibrillator implantation trial (MADIT)-II","volume":"47","author":"Zwanziger","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/eurheartj\/ehs090","article-title":"The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis","volume":"34","author":"Smith","year":"2013","journal-title":"Eur Heart J"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1161\/01.CIR.0000015504.57641.D0","article-title":"Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the antiarrhythmics versus implantable defibrillators (AVID) economic analysis substudy","volume":"105","author":"Larsen","year":"2002","journal-title":"Circulation"},{"key":"B84","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1016\/j.jacc.2005.08.033","article-title":"Cost effectiveness of cardiac resynchronization therapy in the comparison of medical therapy, pacing, and defibrillation in heart failure (COMPANION) trial","volume":"46","author":"Feldman","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1540-8167.2012.02413.x","article-title":"Cost-effectiveness of cardiac resynchronization therapy in the MADIT-CRT trial","volume":"24","author":"Noyes","year":"2013","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"417","DOI":"10.7326\/M14-1804","article-title":"Cost-effectiveness of adding cardiac resynchronization therapy to an implantable cardioverter-defibrillator among patients with mild heart failure","volume":"163","author":"Woo","year":"2015","journal-title":"Ann Intern Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jval.2015.02.001","article-title":"Cost-effectiveness analysis alongside clinical trials II-an ISPOR good research practices task force report","volume":"18","author":"Ramsey","year":"2015","journal-title":"Value Health"},{"key":"B88","doi-asserted-by":"publisher","first-page":"v93","DOI":"10.1093\/europace\/eup274","article-title":"Is cardiac resynchronization therapy cost-effective?","volume":"11","author":"Boriani","year":"2009","journal-title":"Europace"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1136\/heartjnl-2015-308883","article-title":"Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure","volume":"102","author":"Mealing","year":"2016","journal-title":"Heart"},{"key":"B90","first-page":"30","article-title":"Medications associated with implantable cardiac devices","volume":"41","author":"Koski","year":"2016","journal-title":"US Pharm"},{"key":"B91","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.hrthm.2011.11.022","article-title":"Implantable cardioverter-defibrillator longevity under clinical circumstances: an analysis according to device type, generation, and manufacturer","volume":"9","author":"Thijssen","year":"2012","journal-title":"Heart Rhythm"},{"key":"B92","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609758","article-title":"Declining risk of sudden death in heart failure","volume":"377","author":"Shen","year":"2017","journal-title":"N Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator implantation in patients with nonischemic systolic heart failure","volume":"375","author":"Kober","year":"2016","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1001\/jamacardio.2017.0630","article-title":"Primary prevention implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy: a meta-analysis","volume":"2","author":"Al-Khatib","year":"2017","journal-title":"JAMA Cardiol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jacc.2022.07.019","article-title":"Randomized trial of left bundle branch vs. biventricular pacing for cardiac resynchronization therapy","volume":"80","author":"Wang","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/pace.14405","article-title":"Left bundle branch pacing in heart failure patients with left bundle branch block: a systematic review and meta-analysis","volume":"45","author":"Cheng","year":"2022","journal-title":"Pacing Clin Electrophysiol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jacep.2022.09.002","article-title":"Catheter ablation of ventricular tachycardia in patients with structural heart disease: a meta-analysis","volume":"2","author":"Virk","year":"2022","journal-title":"JACC Clin Electrophysiol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1016\/j.hrthm.2017.10.035","article-title":"2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines and the heart rhythm society","volume":"15","author":"Al-Khatib","year":"2018","journal-title":"Heart Rhythm"},{"key":"B99","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jacep.2018.01.007","article-title":"Cost effectiveness of ventricular tachycardia ablation versus escalation of antiarrhythmic drug therapy: the VANISH trial","volume":"4","author":"Coyle","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"e001155","DOI":"10.1136\/openhrt-2019-001155","article-title":"Cost-effectiveness of ablation of ventricular tachycardia in ischaemic cardiomyopathy: limitations in the trial evidence base","volume":"7","author":"Chen","year":"2020","journal-title":"Open Heart"},{"key":"B101","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1161\/01.CIR.101.3.280","article-title":"Cost-effectiveness of catheter ablation in patients with ventricular tachycardia","volume":"101","author":"Calkins","year":"2000","journal-title":"Circulation"},{"key":"B102","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1513614","article-title":"Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs","volume":"375","author":"Sapp","year":"2016","journal-title":"N Engl J Med"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1161\/CIRCULATIONAHA.122.059598","article-title":"Does timing of ventricular tachycardia ablation affect prognosis in patients with an implantable cardioverter defibrillator? Results from the multicenter randomized PARTITA trial","volume":"145","author":"Della Bella","year":"2022","journal-title":"Circulation"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.jacc.2022.01.050","article-title":"Substrate ablation vs. antiarrhythmic drug therapy for symptomatic ventricular tachycardia","volume":"79","author":"Arenal","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1161\/CIRCULATIONAHA.122.060039","article-title":"First-line catheter ablation of monomorphic ventricular tachycardia in cardiomyopathy concurrent with defibrillator implantation: the PAUSE-SCD randomized trial","volume":"145","author":"Tung","year":"2022","journal-title":"Circulation"},{"key":"B106","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0168-8510(99)00079-2","article-title":"A qualitative study of the extent to which health gain matters when choosing between groups of patients","volume":"51","author":"Dolan","year":"2000","journal-title":"Health Policy"},{"key":"B107","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1046\/j.1369-6513.2002.00182.x","article-title":"Resource allocation, social values and the QALY: a review of the debate and empirical evidence","volume":"5","author":"Schwappach","year":"2002","journal-title":"Health Expect"},{"key":"B108","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12913-018-3162-2","article-title":"Will the reformed cancer drugs fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals","volume":"18","author":"Morrell","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.cjca.2022.07.003","article-title":"Open access budget impact assessment tools: a welcome step in supporting evidence-informed policy decisions","volume":"38","author":"Chew","year":"2022","journal-title":"Can J Cardiol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2018.00287","article-title":"Multi-criteria decision analysis (MCDA) models in health technology assessment of orphan drugs-a systematic literature review. Next steps in methodology development?","volume":"6","author":"Baran-Kooiker","year":"2018","journal-title":"Front Public Health"},{"key":"B111","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1586\/14737167.2014.859525","article-title":"How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide","volume":"14","author":"Diaby","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1142429\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T06:04:31Z","timestamp":1682489071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1142429\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":111,"alternative-id":["10.3389\/fcvm.2023.1142429"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1142429","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]},"article-number":"1142429"}}